Zobrazeno 1 - 10
of 210
pro vyhledávání: '"Jj Lafitte"'
Publikováno v:
Immuno-analyse & Biologie Spécialisée. 14:52-61
resume Le Cyfra 21-1 est un marqueur tumoral qui detecte un Fragment de cytokeratine 19. Nous avons evalue son interet au diagnostic en le comparant a l'antigene carcino-embryonnaire (ACE), comme indicateur de l'efficacite therapeutique apres deux cu
Autor:
Marie-Christine Copin, Bernard Gosselin, Michel E. Ribet, Bernard M. Prévost, Anne Brichet, JJ Lafitte
Publikováno v:
The Annals of Thoracic Surgery. 62:830-834
Background Stage I nonirradiated T2 N0 non–small cell lung carcinoma has a postoperative prognosis not very different from stage II irradiated T1 N1 carcinoma. The hypothesis was that more locoregional malignant sites are overlooked in T2 N0 M0 tha
Publikováno v:
European Respiratory Journal. 7:1950-1957
Idiopathic pulmonary fibrosis (IPF) response to corticosteroids and cytotoxic medications appears to be the most important determinant of survival. The purpose of this retrospective study was to analyse the determinants of response to immunosuppressi
Autor:
Alain Tagnon, F Fortin, Dany Brohée, C Vanschaardenburg, P. Mommen, M.C. Berchier, Roger Sergysels, Jean-Sébastien Lecomte, U. Küstner, Richard, Jacques Thiriaux, Jean Klastersky, Jj Lafitte, D Diana, Gérard Bureau, Marianne Paesmans, P Recloux, Jp Sculier
Publikováno v:
International Journal of Oncology.
A phase II trial was conducted to determine the effectiveness of weekly administration of cisplatin (25 mg/m(2) on day 1) and carboplatin (100 mg/m(2) on day 1) as salvage chemotherapy for patients with small cell lung cancer after first-line chemoth
Autor:
CH Marquette, B Stach, E Cardot, JF Bervar, F Saulnier, JJ Lafitte, P Goldstein, B Wallaert, AB Tonnel
Publikováno v:
The European respiratory journal. 8(1)
The optimal amount of systemic corticosteroids to be used in acute severe asthma remains an unresolved issue. In this double-blind, randomized study we compared two doses of methylprednisolone (1 vs 6 mg.kg-1 q.d.) in asthmatics presenting with an ac
Autor:
MH Hannothiaux, A Scharfman, A Wastiaux, L Cornu, E van Brussel, JJ Lafitte, P Sebastien, P Roussel
Exposure to silica can induce fibrosis and/or emphysema. Various factors such as proteases, other hydrolases and oxidants may be involved in the destruction of lung parenchyma. On the other hand, antiproteases play an important role in the protection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8037a6097319571b2d6ddf7d774a20
https://hal-ineris.archives-ouvertes.fr/ineris-00962500
https://hal-ineris.archives-ouvertes.fr/ineris-00962500
Autor:
JP Sculier, M Paesmans, G Bureau, P Recloux, J Baumöhl, O Van Cutsem, MC Berchier, J Thiriaux, JJ Lafitte, P Mommen, P Van Houtte, V Ninane, J Klastersky, null European Lung Cancer Working Party
Publikováno v:
Lung Cancer. 21:S29
Autor:
JJ Lafitte, Fabienne Saulnier, P Goldstein, Benoit Wallaert, J. F. Bervar, E. Cardot, André-Bernard Tonnel, B. Stach, Charles-Hugo Marquette
Publikováno v:
European Respiratory Journal. 8:1435-1435
The optimal amount of systemic corticosteroids to be used in acute severe asthma remains an unresolved issue. In this double-blind, randomized study we compared two doses of methylprednisolone (1 vs 6 mg.kg-1 q.d.) in asthmatics presenting with an ac
Autor:
Ph. Ramon, JJ Lafitte, Gosselin B, Benoit Wallaert, André-Bernard Tonnel, Aerts C, Cyr Voisin
Publikováno v:
Acta Endoscopica. 12:381-396
L'etude quantitative et l'analyse des caracteristiques morphologiques et fonctionnelles des populations cellulaires recueillies par lavage broncho-alveolaire, apportent au clinicien le reflet des desordres physiopathologiques qui se deroulent au nive
Autor:
JJ Lafitte, Guillaume Colin, Demosthenes Makris, Marie Christine Copin, Luc Brun, Charles-Hugo Marquette, Arnaud Scherpereel
Publikováno v:
BMC Cancer, Vol 7, Iss 1, p 150 (2007)
BMC Cancer
BMC Cancer
Background Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse events s